NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.53 by $0.08. The biotechnology company had revenue of $44 million for the quarter, compared to analyst estimates of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. Enanta Pharmaceuticals's revenue was up 388.9% compared to the same quarter last year. During the same period last year, the company posted ($0.28) earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

5 equities research analysts have issued 1-year target prices for Enanta Pharmaceuticals' shares. Their predictions range from $36.00 to $135.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $79.1667 in the next twelve months. This suggests that the stock has a possible downside of 35.3%. View Analyst Ratings for Enanta Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Enanta Pharmaceuticals include Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND) and Dr.Reddy's Laboratories (RDY).

News coverage about ENTA stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.16 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.28 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.10%), James Investment Research Inc. (0.10%), Fisher Asset Management LLC (0.08%), Municipal Employees Retirement System of Michigan (0.02%), Hartford Investment Management Co. (0.02%) and Amalgamated Bank (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including James Investment Research Inc., Hartford Investment Management Co., Amalgamated Bank and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $122.34.

Enanta Pharmaceuticals has a market capitalization of $2.37 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]